Search company, investor...


Founded Year



Acquired | Acquired

Total Raised


About MicroVention

MicroVention, founded in 1997, sells a catheter-based implant for the treatment of cerebral aneurysms as an alternative to an invasive craniotomy. MicroVention's HydroCoilO Embolic System and MicroPlexTM coil system are based on best of breed technology and have proved to be highly effective for the treatment of cerebral aneurysms. In addition, MicroVention recently launched its V-Trak detachment system, a device used to smoothly detach coils from the delivery device in the brain.

Headquarters Location

75 Columbia Suite A

Aliso Viejo, California, 92656,

United States


Missing: MicroVention's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: MicroVention's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

MicroVention Patents

MicroVention has filed 272 patents.

The 3 most popular patent topics include:

  • Vascular diseases
  • Interventional radiology
  • Rare diseases
patents chart

Application Date

Grant Date


Related Topics




Implants (medicine), Vascular diseases, Drug delivery devices, Dosage forms, Vascular surgery


Application Date


Grant Date



Related Topics

Implants (medicine), Vascular diseases, Drug delivery devices, Dosage forms, Vascular surgery



Latest MicroVention News

Intracranial Aneurysm Market Size Will Achieve USD 2,631 Million by 2030 growing at 9.3% CAGR - Exclusive Report by Acumen Research and Consulting

Aug 30, 2022

Electric Bed Market Regional Scope North America, Europe, Asia Pacific, Latin America, and Middle East & Africa Key Companies Profiled B. Braun, Codman Neuro (Integra Life sciences), Johnson and Johnson Services Inc., Medtronic plc, Microport Scientific Corporation, MicroVention Inc. (Terumo Corporation), RAUMEDIC AG, and Stryker Corporation. BIOMODEX. Report Coverage Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis Intracranial aneurysm is a medical condition that results in dilation or ballooning of the blood vessels in the brain. According to the statistics, nearly 3% of the global population is at risk of developing intracranial aneurysm in near future. The rapid adoption of endovascular coiling in the treatment is the leading aspect fueling the intracranial aneurysm market share. Additionally, introduction to technologically advanced products and growing demand for minimally invasive surgeries are the recent intracranial aneurysm market trends that is strengthening the industry growth. A team led by the University of Geneva (UNIGE), the University Hospitals of Geneva (HUG) and the University of Utrecht are studying the genetic determinants of aneurysms, particularly to understand the various forms of the disease and to assess individual risk. The research team will examine the genome of more than 10,000 people suffering from aneurysms compared to that of 300,000 healthy volunteers. So far they have successfully identified 17 genetic abnormalities that are notably involved in the functioning of the vascular endothelium, the inner lining of blood vessels. According to the results published in the journal Nature Genetics, scientists have discovered a potential link between these genetic markers and anti-epileptic drugs. The research shows the possibility for certain drugs in the management of the disease. COVID-19 Impact on the Global Intracranial Aneurysm Market Revenue The COVID-19 outbreak in 2020 has had a severe influence on the intracranial aneurysm market by directly influencing demand and production, causing a disruption in the supply chain and raising the financial burden on enterprises. Brain procedures have frequently been postponed or even cancelled during this interval in order to minimize the transmission of the coronavirus. A large number of studies were also conducted to determine the influence of coronavirus on individuals with intracranial aneurysms. The study discovered that COVID-19 patients may develop neurological problems. This led in multiple occurrences of hemorrhagic and ischemic infarction, which boosted neurology sector sales. As a result, these factors have supported and will continue to support the intracranial aneurysm sector in the coming years. Intracranial Aneurysm Market Dynamics Increasing prevalence of brain aneurysm is the primary factor driving the growth of the global intracranial aneurysm market revenue. Growing research & development activities is another factor boosting the intracranial aneurysm market growth. However, high cost of this treatment is expected to stymie the industry growth. Furthermore, growing cases of hypertension and rising number of stroke worldwide are some of the factors that are creating significant growth opportunities for the market in the coming years. Check the detailed table of contents of the report @ Intracranial Aneurysm Market Segmentation The intracranial aneurysm market is segmented based on type, end-use, and geography. Based on type, the market is divided into surgical clipping, endovascular coiling, flow diverters, and others. According to our intracranial aneurysm market forecast, endovascular coiling accounted for more than 85% in 2021 and is expected to continue its dominance during the projected years from 2022 to 2030. The advantages of this treatment, such as simple access to the multiple aneurysms and vertebrobasilar system in remote places, as well as a quicker recovery period when compared to other procedures, are fueling the endovascular coiling market expansion. By end-use, market segments include hospitals & clinics, ambulatory surgical centers, and others. According to our intracranial aneurysm industry analysis, the hospitals & clinics segment is leading the global intracranial aneurysm market and the segment is also anticipated to maintain its dominance over the forecast period from 2022 to 2030. The complexity of the procedure and the risk associated with the treatment is supporting the selection of hospitals by the patients. Intracranial Aneurysm Market Regional Outlook North America, Europe, Latin America, Asia-Pacific, and the Middle East & Africa are the regional categorizations of the Intracranial Aneurysm market industry. In 2021, North America held the major share (%) in terms of revenue of the global intracranial aneurysm market, and the region is also projected to maintain its dominance over the forecast period from 2022 to 2030. The presence of major players in the region including Johnson and Johnson Services Inc., Medtronic plc, and MicroVention Inc. among others is supporting the regional market value. Buy this premium research report – Intracranial Aneurysm Market Players Some of the leading intracranial aneurysm competitors are B. Braun, Codman Neuro (Integra Life sciences), Johnson and Johnson Services Inc., Medtronic, Microport Scientific Corporation, MicroVention Inc. (Terumo Corporation), RAUMEDIC AG, and Stryker. Intracranial aneurysm companies have announced mergers and acquisitions, partnerships and collaborations, and new product development in order to uplift their position in the global intracranial aneurysm industry. For instance, Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST) has entered into the technology transfer agreement in 2021 with the Biorad Medisys for two biomedical implants including atrial septal defect occluder and intracranial flow diverter stent. According to the Department of Science and Technology (DST), the cost of the indigenous flow diverter stent is expected to be significantly lower than the imported ones which are currently available in the Indian market. Major players are also moving into new regions with advanced technologies for gaining a competitive advantage in the market. Some of the key observations regarding the intracranial aneurysm companies include: • A U.S.-based subsidiary of Terumo, MicroVention, Inc. has announced that it has got approval from the FDA for a new addition to the WEB Aneurysm Embolization System for the treatment of intracranial wide-neck bifurcation aneurysms. The premarket approval (PMA) got Woven EndoBridge (WEB) 17 systems is designed with the latest microbraid technology, features a lower profile delivery system compatible with the VIA™ 17 microcatheter, and includes additional device configurations. • Frost & Sullivan recognized RapidAI with the Global Company of the Year Award 2020. The recognition is received for the global AI-based stroke imaging and diagnosis market segment. Rapid ICH uses Artificial intelligence (AI) to quickly triage NCCT scans to identify suspected intracranial hemorrhages (ICH). • A new device for the treatment of intracranial aneurysms has received European CE Mark approval in 2020, announced by the medical device company Cerus Endovascular. The newly approved device is a unique, fine mesh braid that is deployed across the neck of the aneurysm sac and provides a combination of flow disruption and flow diversion through a single device implant. Questions Answered By This Report What was the market size of Intracranial Aneurysm Market in 2021? What will be the CAGR of Intracranial Aneurysm Market during the forecast period from 2022 to 2030? Who are the major players in Global Intracranial Aneurysm Market? Which region held the largest share in Intracranial Aneurysm Market in 2021? What are the key market drivers of Intracranial Aneurysm Market? Who is the largest end user Intracranial Aneurysm Market? What will be the Intracranial Aneurysm Market value in 2030? Browse More Research Topic on Healthcare Sector: The Global Endometrial Ablation Market is anticipated to grow at a CAGR of around 5.5% during the forecast period 2021 to 2028 and to reach around USD 1,372.6 Million by 2028. The Global Cell and Tissue Preservation Market is anticipated to grow at a CAGR of around 11.5% during the forecast period 2021-2028. The market was valued at around USD 2.9 Billion in 2020. The Global Pancreatic Cancer Therapeutics Market Size was valued at USD 3,582 Million in 2021 and is predicted to be worth USD 6,575 Million by 2030, with a CAGR of 7.2% from 2022 to 2030. Acumen Research and Consulting is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact-based decisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise. For Latest Update Follow Us on Twitter and, LinkedIn Contact Us:

MicroVention Frequently Asked Questions (FAQ)

  • When was MicroVention founded?

    MicroVention was founded in 1997.

  • Where is MicroVention's headquarters?

    MicroVention's headquarters is located at 75 Columbia, Aliso Viejo.

  • What is MicroVention's latest funding round?

    MicroVention's latest funding round is Acquired.

  • How much did MicroVention raise?

    MicroVention raised a total of $51.6M.

  • Who are the investors of MicroVention?

    Investors of MicroVention include Terumo, Crosspoint Venture Partners, Advanced Technology Ventures, Delphi Ventures, De Novo Ventures and 7 more.

  • Who are MicroVention's competitors?

    Competitors of MicroVention include AcuFocus, Neoss, Endologix, Aptus Endosystems, Aeris Therapeutics and 11 more.

Compare MicroVention to Competitors

Varix Medical

Varix Medical Corporation, located in Sunnyvale, Calif., is a medical device company focused on developing products for the minimally invasive treatment of chronic venous insufficiency, commonly referred to as "varicose veins." For patients with advanced stages of varicose veins, laser- and RF-based (radiofrequency) treatments have been developed, but each device has deficiencies making them less-than-optimal solutions. Varix Medical's platform technology will enable physicians to efficiently and effectively treat more types of diseased veins than is currently possible when using either laser or RF devices. Additional treatable vessels include tortuous sub-truncal vessels and other visible smaller varicose veins. The Varix platform employs a vapor-based endovenous ablation system that will consist of a disposable catheter, a catheter introducer or delivery system, and a reusable vapor generator. RCT and Coronis Medical Ventures LLC., formed Varix in August 2007 and acquired the technology under license from Tsunami MedTech LLC. Coronis and RCT have been the primary in investors in Varix.

Spineology Logo

Spineology provides anatomy-conserving spinal technologies for surgeons and their patients. Spineology surgical techniques conserve spinal bone, ligament, and muscle tissue. Spineology is committed to increasing procedural efficiency, reducing surgical morbidity, and accelerating patient recovery.


SpineForm is developing a less invasive spinal deformity surgical treatment. SpineForm's HemiBridge is a spinal implant designed to help correct and straighten spinal deformities in growing children, without the need for a brace or extensive future spinal fusion surgeries.

NeoChord Logo

NeoChord is a medical technology company engaged in the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company's flagship product, the NeoChord Artificial Chordae Delivery System, is a beating heart procedure, echo-guided treatment for patients with mitral valve regurgitation and is proven to resolve and restore normal mitral valve function. The company was founded in 2007 and is based in Minneapolis, Minnesota.

Intersect Partners

Intersect Partners is a California based medical devices company. The company primarily produces intragastric balloons, stent-like neurological medical devices, and associated minimally invasive drug delivery and device systems.

Ark Sciences

Ark Sciences LLC develops pharmaceutical products for animals and their pharmaceutical products are specifically engineered to provide the least invasive, non-surgical sterilization processes possible. Rather than castrating dogs, which can be painful and lead to possibly harmful side-effects, with Ark Sciences' patent protected products, veterinarians and animal welfare specialists have a safe, reliable and cost-effective sterilization treatment.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.